Vaccine start-up scores $300m valuation from venture capitalists
MELBOURNE: An Australian start-up developing a vaccine against one of the world’s most ... read more
New Ingenia boss excites investors with upbeat update
SYDNEY: Ingenia Communities shares have rallied after the rental and holiday accommodation provider ... read more
PharmAust reappoints Michael Thurn just month after his resignation
PERTH: A Perth clinical-stage biotech firm has reappointed its former chief executive to ... read more
